|
Basic Characteristics of Mutations
|
|
Mutation Site
|
E406G |
|
Mutation Site Sentence
|
Four out of the 13 patients acquired a mutation during follow-up; two mutations (G1204E and E406G) appeared as a mixture without clinical impact, while the Q493R mutation emerged in two patients (one receiving bamlanivimab and one receiving bamlanivimab/etesevimab) with fatal outcomes. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
S |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
COVID-19
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
France |
|
Literature Information
|
|
PMID
|
35215820
|
|
Title
|
Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies
|
|
Author
|
Jary A,Marot S,Faycal A,Leon S,Sayon S,Zafilaza K,Ghidaoui E,Quoc SN,Nemlaghi S,Choquet S,Dres M,Pourcher V,Calvez V,Junot H,Marcelin AG,Soulie C
|
|
Journal
|
Viruses
|
|
Journal Info
|
2022 Jan 24;14(2):226
|
|
Abstract
|
We explored the molecular evolution of the spike gene after the administration of anti-spike monoclonal antibodies in patients with mild or moderate forms of COVID-19. Four out of the 13 patients acquired a mutation during follow-up; two mutations (G1204E and E406G) appeared as a mixture without clinical impact, while the Q493R mutation emerged in two patients (one receiving bamlanivimab and one receiving bamlanivimab/etesevimab) with fatal outcomes. Careful virological monitoring of patients treated with mAbs should be performed, especially in immunosuppressed patients.
|
|
Sequence Data
|
-
|